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Abstract 
6R L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) is an essential cofactor for several enzymes including 
phenylalanine hydroxylase and the nitric oxide synthases (NOS). Oral supplementation of BH4 has 
been successfully employed to treat subsets of patients with hyperphenylalaninaemia. More 
recently, research efforts have focussed on understanding whether BH4 supplementation may also 
be efficacious in cardiovascular disorders that are underpinned by reduced nitric oxide 
bioavailability. Whilst numerous preclinical and clinical studies have demonstrated a positive 
association between enhanced BH4 and vascular function, the efficacy of orally administered BH4 in 
human cardiovascular disease remains unclear. Furthermore, interventions that limit BH4 
bioavailability may provide benefit in diseases where nitric oxide over production contributes to 
pathology. This review describes the pathways involved in BH4 bio-regulation and discusses other 
endogenous mechanisms that could be harnessed therapeutically to manipulate vascular BH4 levels. 
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1. Introduction 
6R L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) has, in recent years, garnered considerable attention 
as a therapeutic target for a number of pathologies, notably neurological and cardiovascular 
diseases. The ability of BH4 to affect such a diverse range of biological systems can be attributed to 
its essential cofactor role for numerous enzyme families, namely the aromatic amino acid 
hydroxylases (AAAH) phenylalanine, tyrosine and tryptophan hydroxylase 1, 2, the nitric oxide 
synthases (neuronal/ NOS 1, inducible/NOS 2, endothelial/NOS3) 3, 4 and alkylglycerol mono-
oxygenase ( or glycerylether monooxygenase - GEMO) 5, 6. It is also likely that there are a number of 
other biological roles for BH4 which are yet to be determined 
7.  
 
The pharmacological enhancement of intracellular BH4 levels holds therapeutic promise for a 
number of cardiovascular disorders underpinned by reduced nitric oxide (NO) and thus endothelial 
dysfunction. Conversely, attenuating the rise in intracellular BH4 which occurs in response to 
proinflammatory stimulation would be of benefit in diseases such as inflammatory pain and 
circulatory collapse as observed in septic shock patients. This review summarises the current 
evidence supporting the modulation of BH4 levels and discusses alternate strategies to regulate its 
bioavailability at an intracellular level. 
 
2. BH4 reaction mechanisms 
Endogenous BH4 levels are regulated by a number of highly conserved synthetic and recycling 
enzymes (summarised in Fig. 1) that ensure intracellular BH4 levels are maintained at or below 
saturating levels for enzymes that require it as a cofactor 8. 
 These include the: 
 i) ‘De novo biosynthetic pathway’ utilising GTP as a substrate 
ii) ‘Regeneration/recycling pathway’ which regenerates BH4 following its bioconversion during the 
reactions catalysed by AAAH and GEMO  
 iii) ‘Salvage pathway’ which can regenerate BH4 from 7,8 dihydrobiopterin (BH2). 
 
The de novo biosynthesis of BH4 proceeds in a  Zn
2+, Mg2+ and NADPH-dependent manner from GTP 
via two reaction intermediates; 7,8-dihydroneopterin triphosphate and 6-pyruvoyl-tetrahydropterin. 
The enzymes involved in these reactions are; GTP cyclohydrolase 1 (GCH1), 6- pyruvoyl 
tetrahydropterin synthase (PTPS) and sepiapterin reductase (SR), with the latter step believed to 
occur in two stages with different reaction intermediates 8-11  (Fig. 1). Of these biosynthetic enzymes, 
GCH1 commonly forms the rate limiting step, and thus represents a tractable target for the 
pharmacological manipulation of endogenous BH4 levels. 
 
 
Figure 1: BH4 biosynthetic and regulatory pathways. GCH1, GTP cyclohydrolase 1;  PTPS, Pyruvoyl 
tetrahydropterin synthase; SR, sepiapterin reductase; CR , carbonyl reductase; PAH, phenylalanine 
hydroxylase; NOS, nitric oxide synthase; PCD/dCoH1 pterin-4a-carbinolamine dehydratase; dCoH1dimerization 
cofactor of HNF-1; DHPR, dihydropteridine reductase; DHFR, dihydrofolate reductase. *Sepiapterin reductase 
mediated step during de novo biosynthesis is believed to occur in two stages with two different  reaction 
intermediates, but this has been excluded from the diagram for simplification. †For simplification, tyrosine 
hydroxylase, tryptophan hydroxylase and glyceryl ether monooxygenase  have been excluded from the 
diagram.  
 
Enzymes for which BH4 serves as a cofactor, are all mixed function mono-oxygenases. Mono-
oxygenases utilise molecular oxygen during the reaction, incorporating one oxygen atom into the 
substrate whilst the second oxygen atom is reduced to water. The reaction mechanisms of enzymes 
that use BH4 as a cofactor  have been summarised in extensive reviews and will not be detailed 
further here 8, 10. However, it is important to note that the BH4 turnover products and regeneration 
reactions differ for the different enzyme families (Fig. 1). During the reactions catalysed by PAH and 
other AAAH, BH4 is initially oxidised to tetrahydrobiopterin-4a-carbinolamine and two further 
enzymatic steps are involved in the subsequent dehydration and reduction back to BH4.  
In contrast, it is clear that NOS uses BH4 in a different manner. Numerous functions of BH4 have been 
proposed, including structural stabilisation of the NOS dimer and eliciting conformational changes 
that increase L-arginine binding 12-16 . However, current opinion suggests that a key biochemical 
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mechanism by which BH4 supports NOS mediated catalysis, is through electron donation to the 
heme iron located within the NOS oxygenase domain 17-19. 
During NOS mediated catalysis, electrons originating from the NOS reductase domain, are carried to 
the NOS oxygenase domain, where two successive mono-oxygenase reactions occur. These reactions 
involve the initial oxidation of L-arginine to the intermediate N-hydroxy-L-arginine (NOHA), which is 
then further converted to the end products L-citrulline and nitric oxide (NO) 20. Each of these mono-
oxygenase reactions requires BH4. 
The oxygenase domain contains a ferric heme group and BH4 has been shown to bind in close 
proximity to this group 21. Electrons originating from the NOS reductase domain reduce the ferric 
heme to a ferrous state, enabling O2 to bind. This leads to the formation of a ferric heme-superoxy 
intermediate (FeIII-O2
). It is believed that BH4 donates an electron at this point, thus reducing the 
ferric heme-superoxy species to form a heme-oxy species facilitating L-arginine oxidation. During this 
process, BH4 itself becomes an enzyme bound BH3
+ radical 18, 22-26.  In contrast to AAAH mediated 
catalysis, BH4 does not undergo regeneration by external enzymes, but rather is regenerated from 
the protonated BH3
+ radical by electrons supplied from the NOS reductase domain. 
3. BH4 oxidation and NOS ‘uncoupling’ 
The pathophysiological importance of BH4 during NOS mediated catalysis is apparent in situations 
where BH4 bioavailability is low or absent (due to oxidation or insufficient biosynthesis/recycling). 
Under these circumstances, BH4 is no longer available to reduce the ferric heme-superoxy species in 
NOS, leading to its dissociation and the release of superoxide (O2
) – a phenomenon termed ‘NOS 
uncoupling’. Thus, BH4 deficiency and eNOS uncoupling contributes to endothelial dysfunction not 
only by directly reducing NO production but also by increasing NO scavenging due to O2
 formation. 
This potential for NOS to generate reactive oxygen species is thought to further potentiate vascular 
dysfunction and highlights the importance of sustaining sufficient BH4 levels for full NOS 
functionality, within the intracellular pool.  
BH4 is itself highly susceptible to auto-oxidation, through its interaction with reactive oxygen species 
  in particular peroxynitrite (ONOO), which is formed via the interaction of NO and O2
. During the 
reaction with ONOO, BH4 is believed to initially be converted to a BH3
+ radical which can be further 
oxidised to BH2, although this final step can be prevented by ascorbate 
27.  
A further potential detrimental consequence of BH4 oxidation, is that its oxidation product, BH2 can 
bind to NOS with approximately the same affinity as BH4, but serves no cofactor function. BH2 may 
therefore compete with, or potentially displace, BH4 binding to NOS 
28. Thus, the ratio of BH4:BH2 in 
biological samples, rather than just BH4 alone, may be considered a more important determinant of 
final NOS functionality 29. 
The function of the recycling enzyme dihydrofolate reductase (DHFR) in sustaining BH4 levels is likely 
to become especially important in situations where BH4 has been subject to oxidative inactivation. It 
is known that DHFR regenerates BH4 from BH2 
30 (Figure 1) and biopterins may shuttle into cells via 
specific transporters 31. It remains to be fully determined whether the DHFR pathway itself becomes 
dysfunctional in cardiovascular disease states.  
In summary, insufficiency of BH4 (potentially as a result of oxidation or reduced biosynthesis) leads 
to NOS uncoupling and the subsequent generation of reactive oxygen species, which can further 
oxidise and limit BH4 bioavailability. This may result in a vicious cycle of sustained NOS uncoupling, 
reduced NO bioavailability and enhanced oxidative stress, further potentiating vascular dysfunction.  
Thus, pharmacological interventions that enhance BH4 bioavailability within endothelial cells hold 
significant therapeutic potential for the treatment of numerous cardiovascular disorders. 
4. BH4 and phenylketonurea (PKU) 
BH4 was first identified as a cofactor for the aromatic amino acid hydroxylases (AAAH) and was 
shown to be necessary for the metabolism of phenylalanine, tyrosine and tryptophan 1, 2, 32 and 
consequently the eventual biosynthesis of noradrenaline, dopamine and 5-hydroxytryptamine. 
There are a number of neurological disorders in humans that are related to abnormal BH4 
bioavailability and metabolism 33-38.  Of these, phenylketonurea (PKU) has been especially well 
characterised. Mutations in the phenylalanine hydroxylase (PAH) gene can lead to protein misfolding 
with loss of function and lead to the development of PKU. PKU is characterised by elevated 
circulated phenylalanine (hyperphenylalaninaemia) which can lead to impaired brain development 
and significant mental retardation during early life, and is the most common inborn error of amino 
acid metabolism in European descended populations 39. A strict phenylalanine (L-Phe) restricted diet 
(often with poor patient compliance) was for many years the only strategy implemented to control 
circulating L-Phe levels in PKU patients.  
 
The clinical importance of BH4 was first highlighted following the identification of atypical variants of 
hyperphenylalaninaemia who displayed neurological degeneration despite phenylalanine restriction 
36, 37. Fortunately,  research efforts focused on understanding whether pharmacological BH4 
supplementation could be used to treat PKU patients, led to the clinical development of sapropterin 
dihydrochloride (Kuvan), a synthetic oral BH4 supplement which has been successfully employed to 
increase dietary L-Phe tolerance and maintain blood L-Phe levels within an acceptable range, in a 
subset of hyperphenylalaninaemic patients (termed BH4 responsive) 
40-43.   
 
5. Regulation of nitric oxide bioavailability 
 
Nitric oxide (NO) orchestrates a variety of important biological effects throughout the body, given 
the widespread distribution of the three NOS isoforms. These diverse biological effects include long 
term potentiation and memory formation, smooth muscle vasodilatation, inhibition of platelet 
aggregation and host defence forming part of the inflammatory response to a microbial infection 
44-47. Given the diverse and profound effects of NO on various target tissues, there has been a great 
deal of interest in pharmacologically modulating NO bioavailability.  
 
Following the discovery of endothelium derived relaxing factor and its subsequent identification as 
NO 46, 48 it has become well recognised that impaired vascular NO signalling contributes to the 
phenomenon of ‘endothelial dysfunction’, a hallmark feature of numerous cardiovascular diseases 49-
51. NO supplementation using agents such as organic nitrates (e.g. glyceryl trinitrate and isosorbide 
mononitrate) for the treatment of coronary artery disease, or inhaled NO gas for the treatment of 
pulmonary hypertension in neonates, have been employed clinically for many years. Unfortunately, 
the prolonged use of these agents is often limited by the development of tolerance and potentially 
fatal rebound effects following withdrawal (inhaled NO) 52-55.  
 
Similarly, the inhibition of NOS for the treatment of refractory hypotension in septic shock patients 
showed initial benefits on hemodynamic responses, but overall resulted in an increased mortality 
rate, indicating the complexities of non selectively inhibiting all NOS isoforms 56, 57. 
 
The difficulties associated with regulating vascular NO through the use of direct NO donors/NOS 
inhibitors, naturally led to investigations of endogenous NOS regulatory mechanisms, as an 
alternative method to control NO bioavailability. Such investigations have primarily studied 
interventions that can enhance vascular NO levels for the treatment of endothelial dysfunction and 
include enhancing L-arginine substrate bioavailability 58, 59 and introducing antioxidants to limit the 
destruction of NO by reactive oxidant species 60, 61.  Unfortunately, studies investigating the chronic 
administration of these agents suggests that such interventions lack clear efficacy and in some cases 
worsen outcome, although it should be noted that there are inherent complexities with the design 
of these types of clinical trial 62-66.  
 
Another possible target for regulating NO levels is the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH). DDAH metabolises the endogenously produced NOS inhibitors, 
asymmetric dimethylarginine (ADMA) and L-NG monomethyl-L-arginine (L-NMMA). However, to date 
only selective inhibitors of DDAH (which lead to an increase in ADMA) have been developed, 
suggesting that DDAH may be a more tractable target for diseases characterised by elevated NO 
such as inflammation and septic shock 67-70. Pharmacological DDAH activators may however, be 
successfully developed in the future as a method to reduce endogenous ADMA/L-NMMA and 
enhance vascular NO bioavailability within the cardiovascular system. 
 
6. Regulation of BH4 and vascular function 
 
Intensive investigation over recent years has focused on understanding whether increasing BH4 
levels may also elicit therapeutic benefits for the treatment of cardiovascular disorders underpinned 
by endothelial dysfunction. Numerous rodent and clinical studies investigating genetic (GCH1 gene 
manipulation or human polymorphisms) have shown that loss of GCH1 activity exacerbates vascular 
dysfunction whilst over expression is protective, as described within section 7.1. Similarly animal 
studies and small scale acute clinical studies using pharmacologically supplemented BH4, have 
demonstrated a correlation between enhanced BH4 levels and improved vascular function 
71-99 and 
Tables 1 and 2. The chief limitation of these clinical studies, was the high doses of BH4 administered 
50-100 μM compared to physiological plasma levels of 1050 nM 100 which may have elicited NOS 
independent or other non specific effects 96, 101, 102.  Furthermore, only the acute vascular effects of 
BH4 were assessed in these clinical studies and BH4 was typically delivered via an intracoronary/intra 
arterial infusion, which is unrepresentative of a suitable route of administration for chronic disease 
management. 
 
Clinical trials investigating oral BH4 supplementation have shown varied efficacy in numerous 
disorders with an apparent lack of efficacy in diseases such as hypertension and coronary artery 
disease 103-110 and Table 3.  These findings may be explained by either rapid clearance of BH4 after 
oral administration and/or enhanced oxidation following adsorption, with a consequent decrease in 
the vascular BH4:BH2 ratio, despite a clear elevation of BH4   in the plasma pool 
103. Indeed, co-
administration with ascorbate has been shown to enhance BH4 bioavailability and in certain cases 
improve vascular function, possibly through chemical stabilisation and increased regeneration of 
BH3
+ to BH4 
29, 106, 108, 111, 112. However, studies in larger cohorts of patients would be required to 
determine whether this dual (BH4 plus antioxidant) intervention would be efficacious on a chronic 
basis. 
 
The cellular deposition of BH4 after administration appears to be cell type dependent and either 
involves direct uptake of BH4 or initial oxidation to BH2 and subsequent reduction back to BH4 by 
dihydrofolate reductase (DHFR) via the salvage pathway 30. An emerging literature indicates that 
DHFR also plays an important role in the maintenance of cellular BH4 levels and NOS functionality. 
Enhanced hydrogen peroxide production arising from angiotensin II treatment reduces DHFR 
expression, siRNA knockdown of DHFR exacerbates NOS uncoupling and DHFR over expression elicits 
a restorative effect 113-116. These studies suggest that DHFR may itself represent a therapeutic target 
for regulating vascular BH4 levels and NOS functionality.  
 
Thus, whilst the evidence clearly suggests that enhancing BH4 within endothelial cells is beneficial, 
these recent clinical trials suggest that there are limitations to achieving this pharmacologically. The 
vascular effects following oral administration of BH4 appear complex and dose dependent 
87, 103.  The 
ratio of BH4:BH2 achieved within vascular endothelial cells may influence outcome and oral BH4 
supplementation could counter-intuitively elicit harmful effects through enhanced prevalence of the 
BH2 species 
87, 103. A detailed understanding of both the endogenous regulation of BH4 in normal 
physiology and pathophysiology, its cellular uptake/recycling and the fate of orally administered BH4, 
appears necessary in order to develop safe, rational BH4 modifying strategies for the treatment of 
endothelial dysfunction 117.  
  
 Table 1 Effects of pharmacological BH4 administration in animal studies 
 
 
Table 2.  Acute effects of BH4 supplementation in human cardiovascular disease 
Treatment Cardiovascular effect Species Reference
BH4 augmented relaxation induced by acetylcholine in diabetic aortic rings Rats 82
BH4 restoration of eNOS function and reduced vascular oxidative stress in insulin-resistant 
rats
Rats 83
BH4 Improves endothelial function and prevents the development of hypertension in SHR Rats 84
Sepiapterin improved endothelium-dependent vasodilatation in aortas from apoE-/- mice Mice 85
BH4 Improved contractile and metabolic abnormalities in  reperfused hearts Rats 86
BH4 Improves endothelial dysfunction and vascular oxidative stress in microvessels of 
intrauterine undernourished rats
Rats 87
BH4 Prevented the development of hypertension and myocardial hypertrophy associated 
with long-term infusion of Ang II
Rats 88
Sepiapterin Improved vascular relaxation in persistent pulmonary hypertension of newborn only  
when co-administered with superoxide dismutase (MnTMPyP)
Pig 77
BH4 Protection in myocardial ischaemia Rats 81
BH4 Improved endothelial dysfunction, attenuates increased NADPH oxidase mRNA and 
inflammatory factors in the aortas of ApoE-/-mice
Mice 80
BH4 Inhibits hypoxic pulmonary vasoconstriction Rats 79
BH4 Reduced atherosclerosis and in ApoE
-/-mice Mice 89
BH4 Protection following pressure-overload induced hypertrophy. Limited dose range Mice 90
Disease Administration Patient 
number
Outcome Reference
Hypercholesterolemia 6R-BH4 (Alexis Corp.)
10, 100, 500, 1000 g/min for 5 min
13 Restores endothelial dysfunction 91
Diabetes 
(type II)
6R-BH4 (Schricks)
intra-arterial infusion 500 g/min.
23 Improves endothelium dependent vasodilatation 75
Chronic smoking 6R-BH4 (Schricks)
500 µg/min
16 Improves endothelial function 102
Coronary heart disease 6R-BH4 (Alexis Corp.)
intracoronary infusion 10-2 M/min for 2 min 
19 Prevents endothelial dysfunction 92
Hypertension 6R-BH4 (Sigma)
500 mg/min
16 Augments endothelium dependent vasodilatation 
in normotensive and hypertensivespatients
93
Hypercholesterolemia 6R-BH4 (Sigma)
Intracoronary 1mg/min
18 Improves coronary endothelial function 74
Vasospastic angina (VA) 6R-BH4 (Sigma)
Intracoronary 1mg/min; 2 min
28 Improves coronary endothelial function but does 
not prevent coronary spasm in VA patients
94
Coronary artery disease 6R-BH4
4 mg/min 
15 Improves endothelium-dependent vasodilatation 78
Diabetes 
(type II)
6R-BH4 (Schricks)
intra-arterial infusion 500 g/min 
32 Increases insulin sensitivity but does not improve 
endothelial function
101
Hypercholesterolemia 6R-BH4 (Schricks)
10 mg/kg  30 min  i.v. infusion 
19 Improves dysfunction of coronary microcirculation 
in hypercholesterolaemic patients
95
Endotoxin-induced 
endothelial dysfunction
6R-BH4 (Cinalfa)
500 µg/min for 47 min
8 Restores  impaired endothelial function 96
Vascular aging 6R-BH4 (Schricks)
10 mg/kg once 
31 Improves endothelium dependent dilation 97
Vascular aging 6R-BH4(Sigma)
500 mg/min 
37 Prevents endothelial dysfunction 98
Ischemia reperfusion injury 6S and 6R-BH4 and NH4 (Schircks)
500 µg/minH4 
48 Both 6S and 6R BH4 improve 
endothelial function
99
Atherosclerosis 6R-BH4 (Clinalfa)
intracoronary infusion 500 g/min
57 Does not improve endothelial function 100
 Table 3. Oral BH4 supplementation in human cardiovascular disease 
 
In contrast, strategies that attenuate the pathophysiological rise observed in BH4 under 
proinflammatory conditions, may be of benefit in the management of conditions such as pain and 
septic shock 118-122. Such conditions are underpinned by enhanced and sustained over production of 
NO derived from newly transcribed inducible NOS (iNOS) or, in the case of pain, additional increases 
in neurotransmitters such as noradrenaline, generated by AAAH. Understandably, caution must be 
exercised with any treatment strategies that directly limit BH4 bioavailability on a chronic basis, 
given the potentially detrimental impact on NO biology or aromatic amino acid metabolism. 
 
 It is important to note that a greater level of complexity arises with strategies that limit BH4 
bioavailability for NOS. Whilst limiting BH4 may attenuate the extent of an inflammatory response, 
through minimising iNOS dimerisation and activity in vascular smooth muscle, it would be important 
to ensure adequate BH4 bioavailability for eNOS at the level of the microcirculation. Microvascular 
blood flow has been shown to be compromised in patients with sepsis123 and therapeutic strategies 
that improve microvascular perfusion have correlated with reduced multiple organ failure in septic 
patients124.  In these situations, supplementation of NO or BH4 have been suggested to be a method 
to improve microcirculatory function in sepsis125, 126. Clearly the timing of intervention is critical and a 
more complete understanding of the BH4 and NO profiles in sepsis is required in order to develop 
timely strategies for the management of the vascular alterations that occur in septic shock patients. 
 
 
Disease Administration Patient 
number
Outcome Reference
Chronic smoking 2 mg/kg Sapropterin hydrochloride
(single oral dose, measurements taken 
3 and 24hr after admin) Biopten.
17 Improved vascular NO bioactivity-increased
endothelium-dependent vasodilatation
110
Hypertension 1, 5 or 10 mg kg /day of BH4 for 8 wks
Schircks laboratory  (BH4 preparations compounded 
with an equivalent amount of Vit C). 
8
16
Reduced systolic pressure and MAP and 
improvement of endothelial function at
higher doses
109
Hypercholesterolemia 
(LDL>4.5 mmol/L)
400 mg of BH4twice daily over 4 wks.
Schircks laboratory
22 Reversal of endothelial dysfunction and 
oxidative stress
111
Pulmonary arterial 
hypertension 
(Safety study)
2.5 mg/kg to 20mg/kg of Sapropterin 
dihydrochloride over 8 wks. Biomarin
18 Safety study revealed improvement in 6-
minute walk distance
Efficacy trial ongoing
112
Hypertension 5mg/kg of oral Sapropterin dihydrochloride twice 
daily for 8 wks. Biomarin
84 No significant effect on systolic blood 
pressure
NCT00325962
see 108
Endothelial dysfunction 5mg/kg of oral Sapropterin dihydrochloride twice 
daily for 2 wks. Biomarin
52 No significant difference NCT00532844 
see 108
Sickle cell disease Sapropterin dihydrochloride  twice daily, dose 
escalation (every 4 weeks) 2.5, 5, 10 mg/kg/day, and 
20 mg/kg/day for 16 wks. Biomarin
40 Improvement in endothelial function NCT00445978
see 108
Peripheral arterial disease 400 mg of oral Sapropterin dihydrochloride twice 
daily over 24 weeks. Biomarin
190 No significant difference NCT00403494 
see 108
Endothelial dysfunction
Estrogen-deficiency
BH4 10mg/kg  (single oral dose, measurements 
taken 3 hrs after admin)
Schircks laboratory
33 Increased endothelial dependent 
vasodilatation in post menopausal women
113
Coronary artery disease 400 or 700mg/day of Sapropterin dihydrochloride
for 2-6 weeks. Biomarin
49 No significant difference 106
6.1 Other mechanism of action for BH4 
 
Besides the clear cofactor roles of BH4 for AAAH, GEMO and NOS, a number of other roles of BH4 
have been identified. It is clear that BH4 can behave as a direct antioxidant reacting with both 
superoxide 127 and more readily with peroxynitrite (ONOO)27, 82. Indeed the rate constant for the 
reaction between BH4 and ONOO
 is several fold higher than the reactions for other known 
antioxidant systems including ascorbate, glutathione or thiol groups, and likely explains the primary 
antioxidant mechanism of BH4 
27.  
 
BH4 can react with molecular oxygen leading to the production of hydrogen peroxide which has been 
suggested to be an endothelium derived hyperpolarisation factor (EDHF) 128, 129. Supplementation of 
BH4 to iliac arteries modulates arterial function by reducing oxidant stress and enhancing gap 
junctional communication and electrotonic signalling mediated by EDHF, independent of NO 130. 
 
7. GCH1 manipulation and BH4 regulation 
 
One possible method of circumventing the potential problems associated with direct oral BH4 
administration would be to regulate BH4 bioavailability intracellularly, by pharmacologically targeting 
enzymes involved in BH4 biosynthesis or recycling. GCH1 performs the first and, under most 
circumstances, rate limiting step in BH4 biosynthesis. Thus, small molecules that enhance GCH1 
activity would increase BH4 levels and eNOS derived NO within vascular cells for the treatment of 
endothelial dysfunction; whilst strategies that attenuate the inflammation induced rise in GCH1 
activity could limit the bioavailable BH4 for iNOS, as a means to reduce pathophysiological 
inflammation. The remainder of this article will focus on the evidence that supports the 
pharmacological modulation of GCH1 as a tractable target for both enhancing and inhibiting BH4 
bioavailability.  
 
 
7.1 Genetic modification of GCH1 
The availability of genetically modified mice has greatly contributed to our understanding of BH4 
biology in the cardiovascular system. Ubiquitous knockout of GCH1 is lethal in utero but inducible or 
conditional knockout of GCH1 may be feasible. Reduced GCH1, activity as observed in the Hph-1 
mouse (generated by chemical mutagenesis) 131, results in reduced BH4 levels, NOS activity and mice 
exhibit a pulmonary hypertensive phenotype 73, 132. Conversely, endothelial cell targeted over 
expression of GCH1 in mice elevates BH4 levels, NOS activity and NO levels and mice display 
resistance to DOCA-salt induced systemic hypertension, hypoxia induced pulmonary hypertension 
and exhibit reduced atherosclerosis and endothelial dysfunction when crossed with Apo E mice 73, 133, 
134. Following transluminal wire injury, GCH1 over expressing mice also display reduced neointima 
formation 135 . Similarly adenoviral GCH1 gene transfer into endothelial cells enhances NO 
production and eNOS dimerisation and improves vascular function 136  137 whilst siRNA induced 
knockdown elevates blood pressure in mice 138.  
 
There are also a few, albeit small scale, studies in humans indicating that GCH1 polymorphisms 
result in a loss of function phenotype with concomitant detrimental effects on vascular function 139-
142. In summary, loss of function of GCH1 results in predisposition to cardiovascular disease whilst 
over expression appears protective. These effects of experimental gene manipulation or existing 
human polymorphisms appear to be related to BH4 bioavailability and NOS functionality. 
 
 
7.2 Physiological and pharmacological modifiers of GCH1 
There are a number of agents that can stimulate BH4 production, many of which achieve this via 
increasing the expression or activity of GCH1. Up regulation of GCH1 has been reported at the level 
of transcription and translation by hormones including insulin 143 and oestrogen 144, physiological 
stimuli such as shear stress 145 and pharmacological agents including statins 146. These agents are 
known to elicit vascular protective effects and may thus achieve this, in part, through enhanced BH4 
bioavailability for NOS. Indeed, these studies support the observed protective effects of BH4 
supplementation in situations where such endogenous mechanisms have become dysfunctional 72, 
110 
 
Similarly in a pathological setting, proinflammatory cytokines have been shown to upregulate GCH1 
and BH4 levels 
147-149, whilst anti-inflammatory cytokines such as  IL-4 and IL-10 and glucocorticoids 
have been shown to reverse this rise in BH4 
150 151. Proinflammatory cytokines are known to 
contribute to an inflammatory response by transcribing iNOS and enhancing reactive oxygen species 
generation and the generation of micromolar levels of NO, which have both protective antimicrobial 
and deleterious inflammatory effects. Indeed, aberrant iNOS mediated vascular NO production is 
also known to acutely contribute to the circulatory collapse observed in septic shock, and studies 
have shown that inhibition of GCH1 or antagonism of BH4 binding to NOS, elicits protective effects in 
animal models of sepsis 119, 120, 152.  
8.0 Pharmacological enhancers and inhibitors of BH4 bioavailability 
 
As described in section 4.0, a stable preparation of BH4 (sapropterin dihydrochloride) has been 
granted FDA and EMEA approval as a means to regulate blood phenylalanine levels in a subset of 
hyperphenylalaninaemic patients. This compound is currently undergoing clinical investigation in a 
number of cardiovascular diseases although, unfortunately, initial results suggest sapropterin 
dihydrochloride lacks efficacy (Table 3). 
 
Sepiapterin, a precursor which is converted to BH4 via the salvage pathway (dihydrofolate reductase) 
(Fig. 1), is used experimentally to enhance BH4 levels and has been shown to elicit a restorative 
effect of endothelial function in a number of cardiovascular disease models 74, 82, 153. However at high 
concentrations, sepiapterin may lead to an accumulation of 7,8-BH2  which in turn may lead to NOS 
uncoupling and paradoxically elicit detrimental effects 154.  
 
The B vitamin, folic acid has also been shown to elicit beneficial cardiovascular effects by both 
lowering homocysteine levels and through antioxidant effects which are likely mediated by its 
circulating reduced biologically active form, 5-methyltetrahydrofolate (5-MTHF). 5-MTHF 
administration restores BH4 bioavailability, eNOS activity and endothelial function in human tissue 
155, 156. These studies provide further evidence that the oxidative inactivation of BH4 underlies 
numerous cardiovascular pathologies and that strategies limiting BH4 oxidation, hold therapeutic 
promise. Finally, stable compounds that can directly activate NOS via the pterin binding site, have 
been developed. A stable analogue of BH4 (6-acetyl-7,7-dimethyl-7,8-dihydropterin or ADDP)  has 
been shown to substitute for BH4 when the pterin binding site  on NOS is unoccupied, eliciting 
beneficial effects on pulmonary vascular function 157, 158. 
 
Pharmacological inhibitors which block the BH4 biosynthetic or recycling pathways include the 
prototypic GCH1 inhibitor 2,4-diamino-6-hydroxypyrimidine (DAHP) 83, 119, 120, 159-161, and guanine 
mimetics including 8-azaguanine and 8-mercaptoguanine 162;  methotrexate, an inhibitor 
dihydrofolate reductase 30, 116; and N-acetyl-serotonin which can inhibit sepiapterin reductase  
activity 163-165.  
 
Interestingly, some reagents that reduce BH4 bioavailability or BH4 binding to NOS, have 
demonstrated selectivity for iNOS functionality/expression 164, 166. Indeed, of the three NOS isoforms, 
iNOS dimer stability is especially sensitive to BH4 levels 
167. Thus small molecules that attenuate the 
cytokine induced rise in BH4 (normally necessary to support the stabilisation and activity of newly 
formed iNOS) may selectively inhibit iNOS function, potentially by destabilising/preventing dimer 
formation, whilst sparing eNOS mediated NO production.  
 
9.0  GCH1 protein interactions  
A number of GCH1 interacting proteins have been identified through yeast two hybrid and 
immunoprecipitation assays in tissues, some of which appear to be organ specific interactions 7, 168. 
Certain proteins such as tyrosine hydroxylase in drosophila 169, Heat shock protein 90 (Hsp90) related 
proteins and GCH1 feedback regulatory protein (discussed later) 7, 168 can be intuitively linked to the 
role of GCH1 and BH4 in AAAH and NOS functionality. Hsp90 is an essential component of a 
chaperone complex that associates with eNOS and has been shown to be a dynamic regulator of 
eNOS activity in endothelial cells 170. Interestingly GCH1 associates with the activator of Heat Shock 
90 kDa Protein (Aha1) suggesting that this may be a mechanism whereby GCH1 may be recruited 
into endothelial cells to regulate BH4 bioavailability for eNOS 
7. Furthermore, the functional 
significance of the associations between GCH1, Hsp90 and the C-terminus of Hsp70-interacting 
protein (CHIP), have recently been demonstrated in a model of congenital heart disease and 
increased pulmonary blood flow (shunt lambs) where NO signalling is diminished in the pulmonary 
vasculature 171. 
 
Other interacting proteins such as  rabphilin-3A 172,  the mitochondrial protein very long-chain 
specific acyl-CoA dehydrogenase (VLCAD) and eukaryotic translation initiation factors including EIF3I  
indicate that GCH1 may regulate other physiological processes although these remain to be 
demonstrated in functional systems 168.  
 
10.0 Post translational modification of GCH1 
In addition to the pharmacological and physiological GCH1 regulators, GCH1 activity has also been 
shown to be controlled post translationally by phosphorylation 145, 173, 174 and via a functional protein-
protein interaction 175.  
10.1 GCH1 Phosphorylation 
Protein phosphorylation has been shown to modulate GCH1 resulting in elevated activity and an 
increase in cellular BH4 levels. Examination of the amino acid sequence of GCH1 reveals several 
conserved putative phosphorylation motifs for casein kinase II and protein kinase C.  
Agents such as angiotensin II and platelet derived growth factor (PDGF-BB) have been shown to 
stimulate GCH1 phosphorylation in a protein kinase C dependent manner 174.  Of the numerous 
putative phosphorylation motifs on GCH1, serine 81 (within the human sequence) has been shown 
to be functionally important and regulated by laminar shear stress 145. These data suggest that BH4 
bioavailability may be dynamically regulated endogenously via the phosphorylation of GCH1. It still 
remains to be determined whether the other GCH1 phosphorylation motifs are functionally 
important. 
10.2 GCH1 feedback regulatory protein 
In addition to phosphorylation, biochemical studies have demonstrated that GCH1 is also subject to 
allosteric feedback inhibition by BH4 and feed forward activation by the essential amino acid L-
phenylalanine (L-Phe). However, this effect is only seen when GCH1 is bound to GCH1 Feedback 
Regulatory Protein (GFRP) 175.  
A series of elegant studies by Maita et al.,  solved the crystal structures of the rodent GCH1GFRP 
complex (residues 48-241 of GCH1 and residues 1-84 of GFRP) identifying the binding sites and 
interacting residues for both BH4 (BH2 was used experimentally due to increased stability) and L-Phe 
binding within the GCH1GFRP complex 176, 177. Crystallisation of the complete GCH1 protein was not 
possible due to proteolytic cleavage at arginine residues occurring within the first 47 amino acids of 
the N-terminus. Whilst it was suggested that this N-terminal portion was unlikely to be involved in 
substrate binding or catalysis 178, other studies have indicated that this N-terminal portion may 
indeed associate with GFRP and may further elicit regulatory effects on enzyme activity 7, 179. 
 10.3 BH4 mediated inhibition and L-Phe mediated activation of the GCH1GFRP complex 
When present in excess, ten molecules of BH4 bind to the GCH1GFRP complex, within binding 
pockets that are exclusively located on GCH1 176. This binding induces conformational changes within 
the active site (in particular residues Phe-113 and Glu-115) potentially leading to incorrect 
positioning of the substrate GTP, reducing the Vmax of the enzyme and thus reducing GCH1 activity.  
Conversely, inhibition of GCH1 activity can be reversed by ten molecules of L-Phe, which bind 
exclusively within pockets located on GFRP and can stimulate enzyme activity in the presence of sub 
saturating GTP concentrations 177. Thus L-Phe changes the protein complex conformation back to an 
active state and enhances BH4 biosynthesis 
162, 175, 177, 180. Biopterin or L-Phe binding appear to 
enhance the association of GFRP with GCH1 by occupying the spaces at the interfaces thereby 
increasing the surface contact area between the two proteins. 
The interaction of GCH1 with GFRP therefore renders GCH1 sensitive to changes in prevailing BH4 
and L-Phe concentrations. Fluctuations in circulating L-Phe, resulting from altered dietary intake, are 
therefore kept within a physiological range through the feed forward activation of BH4 biosynthesis 
which in turn is a necessary cofactor for the hydroxylation reaction mediated by PAH 1, 175. Similarly, 
BH4 levels are kept within an appropriate physiological range through feedback inhibition of GCH1 
175. 
Despite advances in our understanding of the physical interactions of GCH1 and GFRP 7, 176, 177, 180, the 
functional significance of the GCH1GFRP interactions in vivo, has yet to be fully elucidated.  
However, evidence has demonstrated that these proteins do indeed interact in vivo.  Firstly, an oral 
challenge of L-Phe in humans elicits an increase in plasma biopterin (a measurable correlate of 
plasma BH4) and a rise in plasma and tissue BH4 in mice (Starr and Nandi, unpublished), indicating 
that L-Phe stimulates GCH1 activity in vivo 181, 182. Secondly, administration of L-Phe increases 
endothelium-dependent relaxation and attenuates hypertension in rats made hypertensive by GCH1 
inhibition 183. Finally, human epidermal melanocytes and keratinocytes have the capacity to regulate 
de novo BH4 synthesis via a GCH1GFRP axis, suggesting that the same regulatory axis likely exists in 
other cell types which co-express these two proteins 184. 
Post translational regulation of GFRP has also been reported in vitro. Whilst proinflammatory 
cytokines up regulate GCH1, BH4 levels and iNOS activity, a concurrent down regulation of GFRP 
expression has been reported 185, 186. It has been postulated that this combination of increased GCH1 
and decreased GFRP may render GCH1 insensitive to feedback inhibition by the generated BH4. This 
in turn would provide a continuous supply of BH4 for the newly formed iNOS sustaining a high NO 
output. In contrast, under healthy naïve conditions, cellular BH4 levels are likely to exist in 
sufficiently high concentrations and be tightly bound to eNOS. Thus, any changes in GFRP expression 
would be unlikely to alter eNOS functionality. 
In support of this, we and others have previously demonstrated that over expression of GFRP in 
endothelial cells did not affect basal BH4 and eNOS mediated NO production 
187, 188 but following 
proinflammatory stimulation attenuated the rise in BH4 and consequently dampened iNOS mediated 
NO production 188. Therefore the relative ratio of GCH1:GFRP would likely influence the frequency of 
interaction between the two proteins and hence impact on the extent of feedback inhibition/feed 
forward activation elicited by BH4 and L-Phe. This would subsequently determine the amount of 
bioavailable BH4 and in turn NOS functionality. Whether the ratio of these two proteins is regulated 
and altered during pathophysiology, remains to be investigated. 
In addition to proinflammatory stimuli, laminar shear stress appears to regulate the GCH1-GFRP 
complex. Laminar shear – a physical stimulus which is known to elicit vascular protective effects (as 
opposed to oscillatory shear), has been shown to phosphorylate GCH1 (Ser-81) leading to a 
significant increase in BH4 levels 
145. Interestingly, a recent study by the same group demonstrated 
siRNA mediated knockdown GFRP enhanced GCH1 phosphorylation and that laminar shear caused in 
a disassociation between GFRP and GCH1 189. This data provides further evidence that modification 
of GCH1-GFRP protein-protein interactions and associations may have the capacity to regulate BH4 
levels in pathophysiology. 
10.4 GCH1GFRP protein-protein interactions – a druggable target? 
The pharmacological modulation of the allostery or physical interactions between GFRPGCH1 offers 
an interesting therapeutic approach to control BH4 bioavailability.  This target is especially attractive 
as it provides the potential for both the activation and inhibition of GCH1, and hence the regulation 
of BH4 in pathologies where NO is either limited (e.g. endothelial dysfunction) (Figure 2) or where 
NO contributes to pathophysiology (inflammatory pain and septic shock) (Figure 3). 
Two GFRP pentamers form a sandwich like complex surrounding one GCH1 homodecamer 176, 177. 
There are 10 identical BH4 binding sites located on the GCH1 homodecamer and 5 identical L-Phe 
binding sites located on each GFRP pentamer. Both sets of ligand binding sites reside within the 
GCH1-GFRP interface 176, 177.  
It has been postulated that the phenylalanine-mediated binding of GFRP locks GCH1 into an active 
conformation such that effective substrate turnover occurs even at low GTP concentrations 175. Small 
molecules that can mimic the conformational changes that occur in response to L-Phe binding, 
therefore have the potential to activate GCH1 and enhance intracellular BH4 levels. Similarly, those 
that mimic the changes induced by BH4 would have the opposite effect in situations where an over 
production of BH4 and NO contributes to pathology. However, it has been argued that these binding 
sites may be poor drug targets because they exist on the interface of two large proteins with a large 
surface area 175, 190.  
 
 Figure 2: Potential mechanisms to enhance BH4 levels to treat endothelial dysfunction. Upper panel illustrates effects of 
insufficient BH4. Lower panel illustrates methods to enhance BH4 by 1) direct exogenous BH4 administration; 2) Small 
molecule activators of GCH1-GFRP complex; 3) Enhancing DHFR mediated conversion of BH2 to BH4  4) antioxidant therapy 
 
Interestingly, advances in the understanding of protein-protein interaction biology 191, 192 have 
suggested that the presence of energetic ‘hot spots’ within protein-protein interfaces that may be 
amendable to pharmacological modification. Thus, a more detailed understanding of the two 
proteins and structural changes that occur in response to feedback inhibition elicited by BH4 and 
feed forward activation elicited by L-Phe, may identify regions other than the known ligand binding 
sites, which could provide a starting point for rational drug design. Such small molecules could either 
mimic the changes induced by L-Phe or BH4 or they could weaken or strengthen the physical 
interaction between the two proteins 193. Whether the GCH1GFRP complex is amenable to this type 
of drug discovery remains to be determined, but a detailed understanding of the biophysical 
interactions between the two proteins in the presence of natural ligands, in normal physiology and 
pathophysiology certainly warrants investigation. 
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11.0 Conclusion 
Elevating vascular BH4 levels for the treatment of diseases characterised by endothelial dysfunction 
holds significant therapeutic potential based on in clinical and preclinical animal model data. 
Similarly attenuating the rise in BH4 during inflammatory states could be used to treat the circulatory 
collapse observed in septic shock patients. Oral administration of BH4 may lack efficacy possibly as a 
result of oxidative inactivation during absorption.  
Manipulation of BH4 levels could be achieved at an intracellular level by targeting the activity of 
enzymes involved in its biosynthesis or recycling. In particular, the rate limiting enzyme, GCH1 can be 
dynamically regulated (i.e. both activated and inhibited) through allosteric interactions when bound 
to its regulatory protein, GFRP. This protein-protein complex may offer a novel mechanism to 
control BH4 bioavailability at a cellular level for the treatment of a broad spectrum of diseases. 
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